一品红(300723.SZ)子公司创新药APH03621片获得临床试验注册申请受理

Group 1 - The core point of the article is that Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received acceptance for the clinical trial application of its innovative drug APH03621 from the National Medical Products Administration [1] - APH03621 is a new oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist (GnRH-ant) developed by the company, intended for the treatment of endometriosis [1]